Combine the new anti-wasting antibody with exercise and protein
A new antibody blocks the hormone that makes people with cancer lose appetite and weight. Weight regained as muscle, not fat, needs exercise and protein alongside it.
GDF-15 is a tumour-derived hormone acting on the brainstem GFRAL receptor to suppress appetite, and a randomised phase 2 of the anti-GDF-15 antibody ponsegromab reported weight gain and improved appetite in cancer cachexia. Weight gain alone is not the goal: without a resistance training and protein stimulus, regained mass is likely to be fat rather than functional muscle.
- Cachexia, toxicity and the limits of the patient · Patients often die of wasting or cannot tolerate the doses that would work. Treating the patient, not just the tumour, lags far behind.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.
Pages like this
not linked directly; found by shared links- IdeaTreat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles
Shares Resistance training and protein for cachexia and sarcopenia, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Pfizer (incl. Seagen).
- TechnologyCachexia-directed therapy (GDF-15 blockade)
Shares Ponsegromab phase 2 in cancer cachexia, Resistance training and protein for cachexia and sarcopenia, Exercise & lifestyle oncology, Pfizer (incl. Seagen).
- IdeaCatch wasting early with a smart scale and a step counter
Shares Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Toxicity and quality of life are undervalued, Pancreatic ductal adenocarcinoma.
- IdeaPay for supervised exercise the way we pay for drugs
Shares CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer, Structured exercise prescribed like a drug in all curative-intent cancer care, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology.
- IdeaSelect cachexia trial patients by the hormone driving their wasting
Shares Ponsegromab phase 2 in cancer cachexia, Cachexia, toxicity and the limits of the patient, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- IdeaFour weeks of training and nutrition before major cancer surgery, as standard
Shares Structured exercise prescribed like a drug in all curative-intent cancer care, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Pancreatic ductal adenocarcinoma.
- IdeaTest protein and resistance training during immunotherapy
Shares Structured exercise prescribed like a drug in all curative-intent cancer care, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Non-small-cell lung cancer.
- IdeaTrials of structured cognitive rehabilitation for cancer-related cognitive impairment
Shares Structured exercise prescribed like a drug in all curative-intent cancer care, Exercise & lifestyle oncology, Toxicity and quality of life are undervalued.